脂肪分布与TGR5表达和子宫内膜癌临床病理特征及预后的关联
该回顾性队列研究纳入146例子宫内膜癌(EC)患者和153例良性病变对照,随访术后1年,发现血清TGR5、内脏脂肪面积(VFA)、皮下脂肪面积(SFA)及BMI升高与EC术后1年内复发转移风险增加独立相关,且四指标联合检测诊断效能优于单一指标。
要点
- 高血清TGR5、高VFA、高SFA及高BMI是EC根治术后1年内复发转移的独立危险因素。
- 血清TGR5≥7.7 μg/L、VFA≥90.4 cm²、SFA≥221.6 cm²、BMI≥23.9 kg/m²时复发转移风险显著增加。
- 四项指标联合检测对EC术后复发转移的诊断效能优于单一指标检测。
核心结论
- 高血清TGR5、高VFA及高SFA的EC患者复发转移率较高。
- 高血清TGR5、高VFA、高SFA及高BMI是EC根治术后1年内复发转移的独立危险因素。
- 四项指标联合检测的诊断效能优于单一指标检测。
研究设计与样本
- 本研究为回顾性队列研究,纳入2020年3月至2024年3月在西北妇女儿童医院行腹腔镜EC根治术的146例EC患者作为EC组。
- 同期153例子宫内膜良性病变患者作为对照组。
- EC组随访术后1年,根据是否复发转移分为复发转移亚组(45例)和未复发转移亚组(101例)。
主要发现
- 复发转移亚组血清TGR5、VFA、SFA及BMI均明显高于未复发转移亚组(P均<0.05)。
- 复发转移亚组和未复发转移亚组的上述4项指标均明显高于对照组(P均<0.05)。
- Cox回归显示血清TGR5≥7.7 μg/L(HR=6.382,95%CI 2.151~18.939,P=0.001)、VFA≥90.4 cm²(HR=6.914,95%CI 2.279~20.979,P=0.001)、SFA≥221.6 cm²(HR=7.520,95%CI 2.414~23.421,P=0.001)、BMI≥23.9 kg/m²(HR=9.434,95%CI 3.019~29.473,P<0.001)为术后1年内复发转移的危险因素。
- TGR5高表达、VFA高水平及SFA高水平组术后复发转移概率更高,无复发生存(RFS)时间更短(P均<0.05)。
- ROC曲线显示四项指标联合检测诊断效能优于TGR5、SFA、BMI单一指标检测(P均<0.05)。
关键数值与推荐
- 血清TGR5表达水平7.7 μg/L、VFA 90.4 cm²、SFA 221.6 cm²、BMI 23.9 kg/m²分别为各指标约登指数最大时的截断值。
- 血清TGR5≥7.7 μg/L的HR=6.382(95%CI 2.151~18.939,P=0.001)。
- VFA≥90.4 cm²的HR=6.914(95%CI 2.279~20.979,P=0.001)。
- SFA≥221.6 cm²的HR=7.520(95%CI 2.414~23.421,P=0.001)。
- BMI≥23.9 kg/m²的HR=9.434(95%CI 3.019~29.473,P<0.001)。
临床怎么用
- 对EC根治术后患者可检测血清TGR5、VFA、SFA及BMI,用于评估1年内复发转移风险。
- 上述指标超过截断值时提示复发转移风险增高,可考虑加强随访。
- 联合检测四项指标可能提高对EC术后复发转移的诊断效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effects of visceral fat and subcutaneous fat distribution and the expression level of serum Takeda G protein-coupled receptor 5 (TGR5) on the clinicopathologic features and postoperative recurrence and metastasis of patients with endometrial cancer (EC). Methods: This was a retrospective cohort study. A total of 146 EC patients who underwent laparoscopic radical resection of EC at Northwest Women and Children's Hospital from March 2020 to March 2024 were enrolled as the EC group, and 153 concurrent patients with benign endometrial lesions were enrolled as the control group. The EC group was followed up for 1 year after the surgery to analyze the prognosis. Depending on whether recurrence and metastasis occurred, the EC group was further divided into the recurrence or metastasis subgroup (n=45) and the non-recurrence or metastasis subgroup (n=101). Age, obstetric history, body mass index (BMI), serum TGR5 level, visceral fat area (VFA) and subcutaneous fat area (SFA) were collected and compared between the recurrence or metastasis subgroup, non-recurrence or metastasis subgroup and the control group. The area under curve, sensitivity, specificity and the Youden index of the predictive value of TGR5 expression level, VFA level, SFA level, and BMI in patients in the EC group were analyzed using receiver operating characteristic (ROC) curves. Based on the cut-off value determined by the Youden index, the patients in the EC group were further classified into high-expression/high-level and low-expression/low-level groups. Univariate and multivariate Cox proportional hazards regression models were used to identify the risk factors for recurrence and metastasis of patients in the EC group in 1 year. The one-year recurrence and metastasis of EC patients with different serum TGR5 expression levels, VFA levels, SFA levels and BMI were analyzed, survival curves were plotted and data of recurrence-free survival (RFS) were obtained using the Kaplan-Meier method. ROC curves were constructed to evaluate the diagnostic efficacy of serum TGR5 expression level, VFA level, SFA level, BMI and their combined indicators. Results: The serum TGR5 expression level, VFA level, SFA level and BMI were significantly higher in the recurrence or metastasis subgroup compared to the non-recurrence or metastasis subgroup (all P<0.05). Furthermore, all four indicators in both the recurrence or metastasis subgroup and the non-recurrence or metastasis subgroup were significantly higher than those in the control group (all P<0.05). When the serum TGR5 expression level was 7.7 μg/L, the VFA level was 90.4 cm², the SFA level was 221.6 cm², and the BMI was 23.9 kg/m², the Youden index reached its maximum value for each respective parameter. Cox regression analyses revealed that serum TGR5≥7.7 μg/L (HR=6.382, 95%CI:2.151-18.939, P=0.001), VFA≥90.4 cm² (HR=6.914, 95%CI:2.279-20.979, P=0.001), SFA≥221.6 cm² (HR=7.520, 95%CI:2.414-23.421, P=0.001) and BMI≥23.9 kg/m² (HR=9.434, 95%CI:3.019-29.473, P<0.001) were risk factors for recurrence and metastasis within 1 year after surgery. The incidence of postoperative recurrence and metastasis in the high TGR5 expression group, high VFA level group and high SFA level group were significantly higher, while the RFS times were significantly shorter than those in the low TGR5 expression group, low VFA level group and low SFA level group (all P<0.05). ROC curve analysis showed that the above independent factors had good evaluation efficacy, and the combined detection was superior to single indicator detection. Conclusions: EC patients with high serum TGR5 expression level, VFA level and SFA level have a higher recurrence and metastasis rate. High serum TGR5 expression level, high VFA level, high SFA level and high BMI are risk factors for recurrence and metastasis within 1 year after radical resection of EC, and the diagnostic value of combined detection is superior to single indicator detection. 目的: 探索内脏及皮下脂肪分布以及血清Takeda G蛋白偶联受体5(TGR5)表达水平与子宫内膜癌(EC)患者临床病理特征的关系及其对预后的影响。 方法: 本研究为回顾性队列研究,收集西北妇女儿童医院2020年3月至2024年3月行腹腔镜EC根治术的146例EC患者作为EC组,并以同期153例子宫内膜良性病变患者作为对照组,随访EC组患者术后1年的预后,根据是否发生复发转移,将EC组患者分为复发转移亚组(45例)与未复发转移亚组(101例)。收集比较复发转移亚组、未复发转移亚组与对照组患者年龄、孕产史、体重指数(BMI)、血清TGR5表达水平、内脏脂肪面积(VFA)及皮下脂肪面积(SFA)。采用受试者工作特征(ROC)曲线评估TGR5表达水平、VFA水平、SFA水平及BMI对EC组患者复发情况的预测价值,计算上述4个指标的曲线下面积、敏感度、特异度及约登指数,并确定最佳截断值,以此将EC组患者进一步分为高表达或高水平与低表达或低水平。通过单因素及多因素Cox回归比例风险模型分析EC组患者1年内复发转移的危险因素。采用Kaplan-Meier法绘制生存曲线并计算不同血清TGR5表达水平、VFA水平及SFA水平的EC组患者无复发生存(RFS)时间。通过绘制ROC曲线验证评价血清TGR5表达水平、VFA水平、SFA水平及BMI及其联合指标的诊断效能。 结果: 复发转移亚组患者血清TGR5表达水平、VFA水平、SFA水平及BMI明显高于未复发转移亚组(P均<0.05),且复发转移亚组及未复发转移亚组患者上述4个指标均明显高于对照组(P均<0.05)。当血清TGR5表达水平为7.7 μg/L、VFA为90.4 cm2、SFA为221.6 cm2以及BMI为23.9 kg/m2时,达到各指标约登指数的最大值。Cox回归分析结果显示,血清TGR5表达水平≥7.7 μg/L(HR=6.382,95%CI为2.151~18.939,P=0.001)、VFA水平≥90.4 cm2(HR=6.914,95%CI为2.279~20.979,P=0.001)、SFA水平≥221.6 cm2(HR=7.520,95%CI为2.414~23.421,P=0.001)与BMI≥23.9 kg/m2(HR=9.434,95%CI为3.019~29.473,P<0.001)为影响患者术后1年内复发转移的危险因素。TGR5高表达、VFA高水平及SFA高水平术后复发转移的概率较TGR5低表达、VFA低水平及SFA低水平患者更高,RFS时间则更短(P均<0.05)。ROC曲线结果显示,TGR5表达水平、VFA水平、SFA水平及BMI 4个指标均具有良好的诊断效能,且4个指标联合检测优于TGR5表达水平、SFA、BMI这3个指标单一指标检测诊断效能,差异均有统计学意义(P均<0.05)。 结论: 高TGR5表达水平、高VFA水平及高SFA水平EC患者复发转移率较高;高血清TGR5表达水平、VFA、SFA、BMI水平均可作为子宫内膜癌根治术后1年内复发转移的独立危险因素,且上述4个指标联合检测优于单一指标检测的诊断效能。.
引用
- Zhao XL, Chu GH, Yu F, et al. [Association of fat distribution and TGR5 expression with clinicopathological features and prognosis in patients with endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2026. PMID: 41765654. doi:10.3760/cma.j.cn112141-20250814-00377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。